Molecular Partners (MOLN) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $13.00 | Apr 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 | Mar 16, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $13.00 | Jan 27, 2026 |
| JP Morgan | Maintained | Neutral | $3.75 from $4.00 | Dec 8, 2025 |
| JP Morgan | Maintained | Neutral | $4.00 from $4.50 | Sep 3, 2025 |
| LifeSci Capital | Initiated Coverage | Outperform | $12.00 | Mar 11, 2025 |
| JP Morgan | Maintained | Neutral | $4.50 from $6.60 | Dec 5, 2023 |
Frequently asked questions
Is MOLN a buy, sell, or hold?
Analysts covering Molecular Partners currently average a Buy rating: 5 buy, 1 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on MOLN?
On Apr 22, 2026, HC Wainwright & Co. maintained Molecular Partners at Buy with a price target of $13.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.